NDAORALTABLET
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
EXFORGE HCT (amlodipine valsartan and hydrochlorothiazide) by Novartis is angiotensin 2 receptor antagonists [moa]. Approved for thiazide diuretic [epc]. First approved in 2009.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXFORGE HCT is a triple-combination oral tablet containing amlodipine (calcium channel blocker), valsartan (ARB), and hydrochlorothiazide (thiazide diuretic) approved in 2009 for hypertension management. It combines three distinct antihypertensive mechanisms to reduce blood pressure in patients requiring multi-drug therapy. The formulation targets patients with moderate-to-severe hypertension who need additive blood pressure control.
$0.988MPart D
LOE ApproachingDeclining
With LOE approaching and modest Part D spending of $988K in 2023, this brand is in defensive mode with limited team expansion opportunities; career moves here focus on managed decline and generic transition planning.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Thiazide Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EXFORGE HCT offers limited career advancement given its LOE-approaching lifecycle and minimal linked job openings; roles available are primarily defensive (managed decline, generic planning, payer relations). Career value lies in lifecycle management expertise and payer negotiation experience as the brand transitions to post-LOE competitive dynamics.
Brand Manager
Worked on EXFORGE HCT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.